| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Kimberly M. Thompson | Q67952803 |
| Radboud J Duintjer Tebbens | Q88309448 | ||
| P2860 | cites work | Infectious Diseases, Public Policy, and the Marriage of Economics and Epidemiology | Q56781257 |
| Countering the posteradication threat of smallpox and polio | Q77317963 | ||
| Policy. OPV cessation--the final step to a "polio-free" world | Q81411439 | ||
| VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION * | Q22255613 | ||
| A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future | Q28261403 | ||
| Choices, beliefs, and infectious disease dynamics | Q34189310 | ||
| New strategies for the elimination of polio from India | Q34582433 | ||
| Polio eradication: the OPV paradox | Q35204255 | ||
| Risk management in a polio-free world | Q36690337 | ||
| Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management | Q36690341 | ||
| Costs and benefits of polio eradication: a long-run global perspective | Q39132372 | ||
| The costs of future polio risk management policies. | Q40258086 | ||
| Retrospective cost-effectiveness analyses for polio vaccination in the United States. | Q40258094 | ||
| The polio eradication effort has been a great success--let's finish it and replace it with something even better | Q40284066 | ||
| The biologic principles of poliovirus eradication | Q41514808 | ||
| Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? | Q43538748 | ||
| Evaluation of response scenarios to potential polio outbreaks using mathematical models | Q44136457 | ||
| Public health. Is polio eradication realistic? | Q46723139 | ||
| Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. | Q50183859 | ||
| Dynamic epidemiology and the market for vaccinations | Q56536052 | ||
| P433 | issue | 9570 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | poliomyelitis | Q12195 |
| P304 | page(s) | 1363-1371 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Eradication versus control for poliomyelitis: an economic analysis | |
| P478 | volume | 369 |
| Q44404419 | A call to address complexity in prevention science research |
| Q35787304 | An economic analysis of poliovirus risk management policy options for 2013-2052 |
| Q27012936 | Can Economic Analysis Contribute to Disease Elimination and Eradication? A Systematic Review |
| Q34632088 | Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. |
| Q35662053 | Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria |
| Q38059027 | Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review |
| Q24614762 | Costs and financial feasibility of malaria elimination |
| Q38006994 | Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. |
| Q44957973 | Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics |
| Q57588859 | Disease eradication is possible and ethical |
| Q58669175 | Disease eradication is possible and ethical |
| Q39823159 | Economic analysis of the global polio eradication initiative. |
| Q39939710 | Effect on seroprevalence of anti-poliovirus antibodies and on vaccination coverage of the implementation of a DTwP-IPV-Hib vaccination programme in a South American city |
| Q38100035 | Enabling implementation of the Global Vaccine Action Plan: developing investment cases to achieve targets for measles and rubella prevention |
| Q28654939 | Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013 |
| Q80799829 | Eradicating polio: the dollars and sense |
| Q80609135 | Eradication versus control for poliomyelitis |
| Q94536902 | Eradication versus control for poliomyelitis |
| Q43350170 | Eradication versus control for poliomyelitis. |
| Q38026922 | Expert review on poliovirus immunity and transmission |
| Q58403325 | Food and biosecurity: livestock production and towards a world free of foot-and-mouth disease |
| Q42200855 | Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples |
| Q34955559 | Free, at last! The progress of new disease eradication campaigns for Guinea worm disease and polio, and the prospect of tackling other diseases. |
| Q34349482 | From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed |
| Q57515350 | Funding of drugs: do vaccines warrant a different approach? |
| Q28473359 | Global eradication of lymphatic filariasis: the value of chronic disease control in parasite elimination programmes |
| Q40037946 | Human movement, cooperation and the effectiveness of coordinated vector control strategies |
| Q36878782 | Inactivated polio vaccine: its proposed role in the final stages of polio eradication |
| Q90123822 | Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan |
| Q49141323 | Is disease eradication ethical? |
| Q28658252 | Mainstreaming modeling and simulation to accelerate public health innovation |
| Q42769414 | Making history: from a public health emergency to a polio-free world |
| Q40226719 | Modeling and Managing the Risks of Measles and Rubella: A Global Perspective Part II. |
| Q40611006 | Modeling and Managing the Risks of Measles and Rubella: A Global Perspective, Part I. |
| Q53335042 | Modeling poliovirus risks and the legacy of polio eradication. |
| Q45326635 | Modeling population immunity to support efforts to end the transmission of live polioviruses |
| Q38754363 | Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases. |
| Q37659611 | Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage. |
| Q29994616 | Operations research in global health: a scoping review with a focus on the themes of health equity and impact |
| Q51701268 | Optimal vaccine stockpile design for an eradicated disease: application to polio. |
| Q39262711 | Policy insights from the nutritional food market transformation model: the case of obesity prevention |
| Q34114356 | Polio eradication is just over the horizon: the challenges of global resource mobilization |
| Q90212492 | Polio: abandoning eradication would result in rapid resurgence of an ancient scourge |
| Q36095404 | Polio: an end in sight? |
| Q90212486 | Polio: from eradication to systematic, sustained control |
| Q38086593 | Preeradication vaccine policy options for poliovirus infection and disease control. |
| Q46892437 | Prioritizing polio. |
| Q36486909 | Rethinking health systems strengthening: key systems thinking tools and strategies for transformational change |
| Q38095550 | Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs |
| Q39247401 | Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system |
| Q36815927 | Systems science methods in public health: dynamics, networks, and agents |
| Q91794046 | The SIPHER Consortium: Introducing the new UK hub for systems science in public health and health economic research |
| Q52589732 | The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. |
| Q41923683 | The cost-effectiveness of an eradication programme in the end game: Evidence from guinea worm disease |
| Q39088922 | The ethics of disease eradication |
| Q46215738 | The lost decade of Global Polio Eradication and moving forward |
| Q37201841 | The pathogenesis of poliomyelitis: what we don't know |
| Q37568832 | The potential impact of expanding target age groups for polio immunization campaigns |
| Q34034190 | The potential impact of immunization campaign budget re-allocation on global eradication of paediatric infectious diseases |
| Q37970528 | The principles and feasibility of disease eradication |
| Q33939084 | The problems with polio: toward eradication |
| Q81358171 | The risks, costs, and benefits of possible future global policies for managing polioviruses |
| Q40009163 | The stages of international (global) health: histories of success or successes of history? |
| Q47681812 | Transfusion Decision Making in Pediatric Critical Illness |
| Q34707400 | Vaccination against polio should not be stopped |
| Q36758719 | World Health Organization's Innovative Direct Disbursement Mechanism for Payment of Grassroots Immunization Personnel and Operations in Nigeria: 2004-2015. |
| Q37235471 | World wide experience with inactivated poliovirus vaccine |
| Q81329830 | [WHO Polio Eradication Programme:Status quo and implementation in Austria] |
Search more.